FirstWord: Market Research Reports

... presents key opinion leader (KOL) views on recent developments in the Colorectal Cancer (CRC) market. Topics covered include: Bristol-Myers Squibb (BMS ... mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC); Roche announcing data from two Phase I studies evaluating ...

... evidence for commercial gain Evidence Matters: Opportunities for Evidence Based Decision-Making breaks down the extensive challenges of evidence ...

... ’t know they exist. Market Access Impact: Asthma/COPD (EU5) shows you how widely prescribed your brand is, and reveals how 7 barriers affect your market share. You ... ; Novartis) Exploring Important Market Access Issues Market Access Impact: Asthma/COPD (EU5) explores key issues affecting drug manufacturers. You’ll learn: How barriers affect market access: What brands do doctors ...

... the ones that are costing you market share. Market Access Impact: Haemophilia B (EU5) shows you how 7 barriers affect your market share, revealing which competitors you ... gamma; Shire) Exploring on Market Access issues Market Access Impact: Haemophilia B (EU5) explores key issues affecting drug manufacturers. You’ll learn: How barriers affect market access: Which brands are ...

... affect your market share, see who you take share from, and who gets your lost share in Market Access Impact: Parkinson’s Disease (EU5). Based on a survey of 150 neurologists from the EU5 countries, the report covers 8 major ...

... treatments get a market share bump of almost 5% because doctors can’t prescribe competitors. Market Access Impact: Asthma/COPD (US) shows you how 7 barriers affect your market share, revealing ... furoate; GSK) Exploring Market Access Barriers Market Access Impact:Asthma/COPD (US) explores key issues affecting drug manufacturers. You’ll learn: How barriers affect market access What brands do doctors ...

... the ones that are costing you market share. Market Access Impact: Haemophilia B (US) shows you how 7 barriers affect your market share, revealing which competitors you ... gamma; Shire) Exploring on Market Access issues Market Access Impact: Haemophilia B (US) explores key issues affecting drug manufacturers. You’ll learn: How barriers affect market access: Which brands are ...

... 7 barriers affect your market share, see who you take share from, and who gets your lost share in Market Access Impact: Parkinson’s Disease (US). Based ... ; US Worldmeds) Exploring Market Access Barriers Market Access Impact: Parkinson’s Disease (US) explores key issues affecting drug manufacturers. You’ll learn: How barriers affect market access: What brands do doctors ...

... your team seize the opportunity? The medical oncologists we surveyed say that medical affairs teams for cancer pain drugs turned in a disappointing performance in the ... team gets right, and where it’s going wrong in Medical Affairs Reputations: Cancer Pain (EU5). Comparing 7 major cancer pain treatments from Kyowa Kirin, Mundipharma/Napp, Takeda ...

... team gets wrong The medical affairs team for a leading melanoma treatment is doing all the right things in the EU5 countries. Oncologists gave it the ... more often or back off a bit. Insight into Medical Affairs Teams for These Melanoma Treatments Imlygic (talimogene laherparepvec; Amgen) Keytruda (pembrolizumab; Merck ...

Disappointing scores show that medical affairs teams need to up their game The medical oncologists we surveyed say that medical affairs teams for cancer pain drugs turned ... team gets right, and where it’s going wrong in Medical Affairs Reputations: Cancer Pain (US). Comparing 6 major cancer pain treatments from Endo Pharmaceuticals, Insys Therapeutics, Mallinckrodt ...

Find out what the leading medical affairs teams are doing right Medical affairs teams for two leading melanoma treatments are doing all the ... your team gets right, and where it’s going wrong in Medical Affairs Reputations: Melanoma (US). Comparing 8 major melanoma treatments from Amgen, Bristol-Myers Squibb, Merck & Co., Novartis ...

... (KOLs)? Which products and combinations are likely to succeed? Learn how KOLs see the MM market evolving in KOL Insight: Multiple Myeloma (MM). Twelve US and European KOLs provide candid insights ... Objectives Questions Asked See the Multiple Myeloma therapies covered Find out who the 6 US and 6 European KOLs are Sample Pages Top Takeaways ...

... how does each of the leading brands compare to its competitors? NPS+ Growth Hormone Deficiency (EU5) gives a unique insight into the overall brand health of 7 leading ... Brand Loyalty Issues NPS+ Growth Hormone Deficiency (EU5) offers valuable insight into brand loyalty from the perspective of those currently prescribing growth hormones. You’ll discover How ...

... how does each of the leading brands compare to its competitors? NPS+ Growth Hormone Deficiency (US) gives a unique insight into the overall brand health of 7 leading ... and 7th June 2017. Explore Important Brand Loyalty Issues NPS+ Growth Hormone Deficiency (US) explores key issues affecting brand loyalty for drug manufacturers ...

How will new combination regimens impact the RCC treatment landscape? The treatment of advanced RCC has been transformed in recent years as VEGF ... for oncologists? In this report six US and six EU KOLs offer their candid insights on ten marketed therapies and five pipeline drugs. Take ... and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success. FirstWord ...

... treatment of rheumatoid arthritis (RA). Topics covered include; KOL views on the Food and Drug Administration’s issuance of a complete response letter, in April 2017, regarding Elli ... product’s delayed entry to this market; the FDA’s approval, in May 2017, of Sanofi and Regeneron’s second-in-class, anti-interleukin-6 (IL-6) inhibitor, Kevzara ...

... how KOLs see the market evolving, and how they expect developers to differentiate their pipeline therapies in KOL Insight: Systemic Lupus Erythematosus (SLE). Twelve North American and European KOLs give their insight on one marketed product, one ...

... presents key opinion leader (KOL) views on recent developments in the type 2 diabetes mellitus market. Topics covered include: AstraZeneca’s announcement of positive top-line ... show superiority for cardiovascular end-point; will it have a role in type 2 diabetes treatment algorithm? If so where? How do KOLs see Bydureon in relation to Trulicity ...

... events that have the potential to impact the treatment landscape of ulcerative colitis (UC). Topics covered include expert opinions on: Takeda announcing the presentation ...

What do Patients want from Pharma? How can pharma leverage patient insights to deliver the support they want? Is patient centricity coming of age? The patient voice is becoming increasingly influential ... from patients and embed a patient centric approach across their organisation. For a real patient-centric perspective turn to What do Patients want from Pharma 2017? In this revealing report, 12 US and EU patient ...

... prices addressed. Real World Data (RWD) and Real World Evidence (RWE) play a key role in building stakeholder confidence and establishing market presence. In Biosimilars Real World Evidence: Proving the point ...

... key opinion leader (KOL) insights on the latest events happening in COPD. Topics covered include expert opinions on Sunovion’s SUN-101 (glycopyrrolate ...

... them at the same rates as other treatments. Market Access Impact: Multiple Sclerosis (EU5) shows you how widely prescribed your brand ... ) Zinbryta (daclizumab; AbbVie/Biogen) Exploring Market Access Barriers Market Access Impact: Multiple Sclerosis (EU5) explores key issues affecting drug manufacturers. You ...

... instead of its competitors. Market Access Impact: Multiple Sclerosis (US) shows you how 7 barriers affect your market share, revealing how ... ; Biogen) Zinbryta (daclizumab; AbbVie/Biogen) Exploring Market Access Barriers Market Access Impact: Multiple Sclerosis (US) explores key issues affecting drug ...

... what your team gets right, and where it’s going wrong in Medical Affairs Reputations: Type 2 Diabetes Mellitus (EU5). Comparing 7 major melanoma treatments from Novo ...

Find out what the leading medical affairs teams in type 2 diabetes are doing right Medical affairs teams for several leading T2DM treatments in the US ... your team gets right, and where it’s going wrong in Medical Affairs Reputations: Type 2 Diabetes Mellitus (US). Comparing 11 major melanoma treatments from ...

MSL Stakeholder Engagement–Meeting Expectations In this report, FirstWord identifies practical solutions to the stakeholder engagement challenges faced by medical science liaisons (MSLs) teams in 2017. Discover on this page 1. The executive ...

... how does each of the leading brands compare to its competitors? NPS+ NSCLC (EU5) gives a unique insight into the overall brand health of 10 leading ... and 13th July 2017. Explore Important Brand Loyalty Issues NPS+ NSCLC (EU5) offers valuable insight into brand loyalty from the perspective ...

... each of the leading brands compare to its competitors? NPS+ NSCLC (US) gives a unique insight into the overall brand ... 2017. Explore Important Brand Loyalty Issues NPS+ NSCLC (US) offers valuable insight into brand ... molecule and biologic treatments to patients with NSCLC. You’ll discover: How satisfied doctors ...

... key opinion leader (KOL) insights on the latest events happening in prostate cancer.Topics covered include expert opinions on; the results of the Phase ... (cfDNA) can be used to assess treatment response in men with advanced prostate cancer who are administered with AstraZeneca's PARP inhibitor Lynparza (olaparib ...

... which class of product? Will payers influence the uptake of pipeline psoriasis drugs? If so, will this be based purely on cost and ... a division with a specific focus on the treatment of inflammatory conditions, including psoriasis, at leading teaching hospitals in Germany. Money Back Guarantee At FirstWord, we ...

... can be learned? Could differences in access to therapy in each European country that took part in the ... for Asthma) guidelines need to be modified? Is more head to head data needed for biologic therapies that ... be used in the treatment of severe eosinophilic asthma, and what challenges face AstraZeneca in terms ...

Winning Payer Support for Companion Diagnostics & Biomakers How can you positively influence payer attitudes to biomarkers and companion diagnostics (CDx)? Biomarkers and CDx are critical ... and regulatory environment Biomarkers Companion diagnostics FDA regulation and guidance for industry Regulatory development in the EU Health technology assessment of companion diagnostics CDx market overview ...

... -term durability and persistence of CAR-T therapies? Which diseases show most benefit to CAR-T treatment and why? Anti-CD19 CAR-T cells have been investigated ... lymphoma (NHL). What are the key opportunities facing CAR-T in each disease and which ones are KOLs most excited about? What ... to the KOLs? How can companies differentiate themselves to market CAR-T therapies? What do CAR-T manufacturers need to do in order to bring these therapies to market in a competitive ...

... , internal communications and performance measurement from frontline MSL staff, look no further than Charting MSL Activity and Performance 2017. Key Benefits Understand which MSL activities are seen as being most important in the US and Europe Benchmark your own MSL ...

... or changed? Market Access Impact: CLL (EU5) examines the dynamics of the CLL drug market in Europe. It specifically looks at how various market access barriers are impacting the 5 most popular CLL drugs from ... on Market Access issues Market Access Impact: CLL provides an up-to-date assessment of the issues affecting current prescribing patterns for CLL drugs. You’ll learn: How barriers affect market access Which CLL ...

... bigger problem Market barriers affect nearly 25% of growth hormone prescriptions in the EU5 countries. Most brands lose market share because of ... Market Access Barriers Market Access Impact: GHD (EU5) explores key issues affecting drug manufacturers. You’ll learn: How barriers affect market access What ...

... 7 barriers affect your market share, see who you take share from, and who gets your lost share in Market Access Impact: Haemophilia A (EU5). Based on a survey ... alfa; Pfizer) Exploring Market Access Barriers Market Access Impact: Haemophilia A (EU5) explores key issues affecting drug manufacturers. You’ll learn: How barriers affect market access: What brands do doctors ...

... or changed? Market Access Impact: CLL (US) examines the dynamics of the CLL drug market in the US. It specifically looks at how various market access barriers are impacting the 6 most popular CLL drugs from ... on Market Access issues Market Access Impact: CLL provides an up-to-date assessment of the issues affecting current prescribing patterns for CLL drugs. You’ll learn: How barriers affect market access Which CLL ...

... than one thing Market barriers affect over 20% of growth hormone prescriptions in the US, and most brands lose market share because of ... Exploring Market Access Barriers Market Access Impact: GHD (US) explores key issues affecting drug manufacturers. You’ll learn: How barriers affect market access What brands ...

... 7 barriers affect your market share, see who you take share from, and who gets your lost share in Market Access Impact: Haemophilia A (US). Based on a survey ... alfa; Pfizer Exploring Market Access Barriers Market Access Impact: Haemophilia A (US) explores key issues affecting drug manufacturers. You’ll learn: How barriers affect market access: What brands do doctors ...

... awareness considerably The role of medical affairs in orphan drug development and commercialisation Summary The medical affairs team tends to play a pivotal role in orphan drug R&D Medical affairs has a critical role in identifying ... in resources for medical affairs highlights its importance for orphan drugs A different approach to non-orphan indications is required The future for medical affairs in orphan drugs Summary Medical affairs will continue to play ...

... report to understand how well your medical affairs team is currently doing, and how they compare to the rest. Medical Affairs Reputations: MS EU5) features 10 leading MS drugs from ... (natalizumab; Biogen) A Competitive Assessment of Medical Affairs Teams Developed with the help of medical affairs specialists, this report compares 10 medical affairs teams and answers key questions ...

... report to understand how well your medical affairs team is currently doing, and how they compare to the rest. Medical Affairs Reputations: MS (US) features 11 leading MS drugs from ... ; AbbVie/Biogen) A Competitive Assessment of Medical Affairs Teams Developed with the help of medical affairs specialists, this report compares 10 medical affairs teams and answers key questions ...

... how KOLs see the market evolving, and how they expect developers to differentiate their pipeline therapies in KOL Insight: Nonalcoholic steatohepatitis (NASH). 6 US and 6 European KOLs give their insight on two off-label marketed products and 12 pipeline programmes. KOLs also provide ...

... from competitors in FirstView’s NPS+ Melanoma 2017 (EU5). Building on the respected net promoter score (NPS), the report compares seven major melanoma drugs with easy ... and 9th, 2017. Explore Important Brand Loyalty Issues NPS+ Melanoma 2017 (EU5) explores key issues affecting brand loyalty for drug manufacturers ...

... satisfaction score in FirstView’s NPS+ Melanoma 2017 (US). Building on the respected net promoter score (NPS), the report compares eight major melanoma drugs with easy ... 3rd and 9th, 2017. Explore Important Brand Loyalty Issues NPS+ Melanoma 2017 (US) explores key issues affecting brand loyalty for drug ...

... be involved in decisions about biosimilars? Will biosimilar oncology mAbs see widespread uptake? What should developers target next? For biosimilars to thrive, payers must ... on clinical and patient biosimilar experience Content Highlights Biosimilars in Europe: current status, key developments Key insights Overview The European biosimilars market continues ...

This update bulletin presents key opinion leader (KOL) views on recent developments in the acute myeloid leukaemia (AML) market. Topics covered include ... enasidenib (AG-221) for the treatment of patients with relapsed/refractory AML with an isocitrate dehydrogenase 2 (IDH2) mutation. Business Questions How do KOLs ...